Skip to content

HIV vaccine that generates broadly neutralising antibodies passes first safety and proof-of-concept study in humans

HIV envelope trimer (triple-component) molecule BG505 SOSIP.

London patient remains HIV-free after 2.5 years off treatment

Ravindra Gupta first presenting the case at CROI 2019 in Seattle. Photo by Liz Highleyman.

HIV vaccine trial failure is a “wake up call” for southern Africa, say researchers

Linda-Gail Bekker and Glenda Gray launching the HVTN 702 study at AIDS 2016 in Durban, South Africa. Photo ©International AIDS Society/Steve Forrest/Workers' Photos

People with HIV more willing to consider a medication offering a 'cure' for HIV than one providing 'clinical remission'

Image: Kostex/Shutterstock.com

“I’m prepared to die to be cured of HIV” – what did people mean when they said this?

Image: Chinnapong/Shutterstock.com

Natural selection is leading to more transmissible HIV in United States

Many people living with HIV unwilling to interrupt treatment for prolonged periods during HIV cure trials

Will post-treatment controllers guide us towards an HIV cure?

Image: nevodka/Shutterstock.com

Second case of unintended HIV transmission during HIV cure study prompts questions about PrEP provision

Image: Adam Gregor/Shutterstock.com